fda warning letters glp-1 compounders september 2025 news takes aim at telehealth companies for promoting unofficial weight loss drug dupes FDA Issues Warning Letters to

doi: 10.1007/s12011-014-0199-x, PMID: [DOI] [PubMed] [Google Scholar] 114.Ziaei S, Kazemnejad A, Sedighi A

As noted by experts at the University of Connecticut, GLP-1 peptide molecules are too large to effectively penetrate the skin barrier, making transdermal delivery of actual GLP-1 medications currently impossible with existing technology

GSH has been demonstrated to be not actively transported into the cell except only a few cell types, notably kidney and intestinal epithelial cells [7, 8]

doi: 10.1002/dta.1941

It means that a product should be studied. The experts who voted against adding these four peptides to the bulks list cited a lack of data to support their use

In the research framing this stack is kept clear of anything that pushes GH or IGF-1 from a third direction at the same time exogenous GH itself, additional GHRPs, or high-dose insulin protocols because the compounding effect on IGF-1 and glucose is precisely the risk the monitoring caveats exist to catch